Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Mayo who wrote (303)	12/23/1998 6:41:00 PM
From: aknahow	Respond to of 712

Yes Cor is presenting but so are other companies which presumably will also try to make it sound positive. I think Patterson's post could be significant if what he describes is happening in other hospitals also. If Institutions really own over 70% of the outstanding stock guess that means a lack of liquidity if you want to buy or sell a big block.

To: Robert Mayo who wrote (303)	12/23/1998 9:44:00 PM
From: aknahow	Read Replies (1) \| Respond to of 712

Robert, this apparently was driving the move. Just found it. Home - Yahoo! - Help [ Business \| US Market \| By Industry \| IPO \| AP \| S&P \| International \| PRNews \| BizWire ] Wednesday December 23, 10:55 am Eastern Time Company Press Release COR Therapeutics CEO Vaughn Kailian talks to The Wall Street Transcript NEW YORK--(BUSINESS WIRE)--Dec. 23, 1998--The Wall Street Transcript has published an in-depth interview with Vaughn M. Kailian of COR Therapeutics, Inc. (Nasdaq:CORR - news), in which he talks at length about his company's future. He says, ''COR Therapeutics is a biotechnology company whose activities are focused on developing drugs and therapeutics for the treatment of severe cardiovascular diseases. The company is about ten years old. We have about 300 hundred employees, including our sales force. And we currently have one product, INTEGRILIN (tm), which is being commercialized by us and our partner, Schering-Plough, in the United States.'' He explains, ''We have had INTEGRILAN (tm) on the market since July, and our joint sales forces have been promoting it at full strength since September. We are already stocked in over 800 hospitals in the United States, and well over 60 percent of those have the product on their formularies.'' Looking forward, he states, ''We're working on an oral blocker of the same receptor. INTEGRILAN (tm) is given intravenously, and it's a very potent inhibitor of a receptor which is called GPIIB-IIIA that allows platelets to stick together and form a clot as they clump up. We're also working on an oral product, a tablet that can be taken orally to treat these same patients after they get released from the hospital and are susceptible to recurring chest pain or heart attacks. Also, we hope this product can be taken to prevent an occurrence from happening in the first place. So the markets do not overlap with the INTEGRILAN(tm) market and really serve to expand the number of severe cardiovascular patients that we're aiming to treat.'' To read the complete interview, go to twst.com. It requires Adobe Acrobat (tm) reader to view the document. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 35 years. The Transcript publishes industry roundtables and interviews with Wall Street analysts, money managers, and Company CEOs, and is read by top money managers, brokers, and individual investors. For subscription information call (800) 246-7673. Contact: The Wall Street Transcript, twst.com Barbara Diliberti (212) 952-7455 Related News Categories: medical/pharmaceutical, publishing Help Copyright © 1998 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina public database, redistributing via a computer network or in a printed form. See our Important Disclaimers and Legal Information. Questions or Comments?